Research from City of Hope and the Translational Genomics Research Institute, part of City of Hope, suggests that loss of a specific RNA molecule, miR-142, may lead to more aggressive forms of chronic myeloid leukemia.Â
Scientists at the Translational Genomics Research Institute, part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product-targeting antibody, for the treatment of pancreatic cancer.Â
A combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a recent study led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center found.
Study data from MAIA Biotechnology, Inc. showed that THIO (6-thio-dG or 6-thio-2’-deoxyguanosine), a first-in-class investigational telomere-targeting agent, demonstrates potent anticancer activity in diffuse intrinsic pontine glioma, one of the most aggressive tumors affecting the central nervous system in children.
FDA approved Braftovi (encorafenib) with Mektovi (binimetinib) for adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
Shasqi, Inc. and Johnson & Johnson Enterprise Innovation Inc. have expanded their ongoing research collaboration.
FirstLook Lung, a blood test that offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT with a negative predictive value of 99.7%, was commercially introduced.Â
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
The FDA Oncologic Drugs Advisory Committee concurred with the FDA staff that the Amgen Inc. confirmatory trial of the lung cancer therapy sotorasib (Lumakras) was uninterpretable as a result of a perceived loss of equipoise.
The FDA Oncologic Drugs Advisory Committee Oct. 4 voted decisively to recommend the first-ever approval supported by a clinical trial that relied on an external control arm—using patient-level data extracted from another trial.
